Bench-to-bedside: NIMH research leads to brexanolone, first-ever drug specifically for postpartum depression

Approximately 1 in 9 women in the United States experiences symptoms.
Source: National Institutes of Health (NIH) News Releases - Category: American Health Source Type: news

Related Links:

Authors: Moore Simas TA, Huang MY, Packnett ER, Zimmerman NM, Moynihan M, Eldar-Lissai A Abstract Objective: To assess healthcare resource utilization (HRU) and costs in children of mothers with and without postpartum depression (PPD). Methods: Administrative claims data from the IBM Watson Health MarketScan® Databases (2010-2016) were used. Women with live births (index date = delivery date) were identified and linked to their newborns. The mother-child pairs were divided into PPD and non-PPD exposure cohorts based on claims for depression, mood or adjustment disorders, or anxiety identified in t...
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
This study was designed to evaluate the efficacy of a mindfulness-based...
Source: BMC Pregnancy and Childbirth - Category: OBGYN Authors: Tags: Research article Source Type: research
Abstract BACKGROUND: Psychosocial adversity escalates medical risk for poor outcomes in infants born
Source: Pediatric Research - Category: Pediatrics Authors: Tags: Pediatr Res Source Type: research
Postpartum depression (PPD) affects10% to 20% of women within the first year after birth and 25% beyond the first year. PPD, despite advances in diagnosis and treatment, remains underdiagnosed and misunderstood. Women do not always display signs of PPD while in care for delivery of the infant and may not discuss mood changes to their primary care provider at discharge and first post-delivery appointment. Identifying screening and treatment options for non –mental health providers was the purpose of this article.
Source: Nursing Clinics of North America - Category: Nursing Authors: Source Type: research
CONCLUSION: Indigenous women are at increased risk of mental health problems during the perinatal period, particularly depression, anxiety, and substance misuse. However, resiliency among Indigenous women, cultural teachings, and methodological issues may be affecting estimates. Future research should utilize more representative samples, adapt and validate diagnostic and symptom measures for Indigenous groups, and engage Indigenous actors, leaders, and related allies to help improve the accuracy of estimates, as well as the well-being of Indigenous mothers, their families, and future generations. TRIAL REGISTRATION: P...
Source: Canadian Journal of Psychiatry - Category: Psychiatry Authors: Tags: Can J Psychiatry Source Type: research
Depression during pregnancy is still often overlooked, even though it happens just as frequently as the postpartum variety.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Authors: Morrison KE, Cole AB, Thompson SM, Bale TL Abstract On March 19, 2019, the United States Food and Drug Administration (FDA) approved Zulresso (brexanolone) for intravenous use for the treatment of postpartum depression (PPD) in adult women. The decision was based on three recent clinical trials following an FDA priority review and breakthrough therapy designation. Brexanolone is now available through a restricted process called the Zulresso Risk Evaluation and Mitigation Strategy Program that requires the drug to be administered by a healthcare provider in a certified healthcare facility. Brexanolone repre...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
Source: Journal of Maternal-Fetal and Neonatal Medicine - Category: Perinatology & Neonatology Authors: Source Type: research
CONCLUSIONS: Most pediatric depression screening protocols assess current manifestations of depressive symptoms. Screening for prospective first onsets of depressive episodes can be better accomplished via an algorithm incorporating rumination, negative affect, and impairment. PMID: 31576786 [PubMed - as supplied by publisher]
Source: Psychological Medicine - Category: Psychiatry Authors: Tags: Psychol Med Source Type: research
This study explored the hypothesis that late gestational reduction of corticosteroids transforms the cerebrovasculature, and modulates postnatal vulnerability to mild hypoxic-ischemic (HI) injury. Four groups of Sprague-Dawley neonates were studied: 1) Sham-Control; 2) Sham-MET; 3) HI-Control; 4) HI-MET. Metyrapone (MET), a corticosteroid synthesis inhibitor, was administered via drinking water from gestational day 11 to term. In Shams, MET administration: 1) decreased reactivity of the Hypothalamic-Pituitary-Adrenal (HPA) axis to surgical trauma in P9 pups by 37%; 2) promoted cerebrovascular contractile differentiation in...
Source: American Journal of Physiology. Regulatory, Integrative and Comparative Physiology - Category: Physiology Authors: Tags: Am J Physiol Regul Integr Comp Physiol Source Type: research
More News: American Health | Depression | National Institutes of Health (NIH) | Postnatal Depression | USA Health | Women